20-Bio-A1 Biomaterials and Biocompatibility · May 2018
Nivaar worked solution (AI-drafted; not reviewed by a licensed engineer)
Paper format: National Exams, May 2018 — 04-Bio-A1 Biomaterials and Biocompatibility. Three hours, open book, any non-communicating calculator. Six questions of equal value (20 marks each, 100 marks total for a complete paper); five constitute a complete exam paper and only the first five appearing in the answer book are marked. All six are solved here, because this set is a study resource rather than an examination script. Most questions require an essay-format answer (materials selection, host response, surface/mechanical characterization); Question 6 additionally asks for an engineering interpretation of a small stress–strain data set, so it quotes and reasons from descriptive statistics computed from the given numbers while still answering in the flowing prose the question calls for.
Reference texts (the books an open-book candidate should have on the desk for this subject):
Question text not reproduced: the examination questions are © Engineers and Geoscientists BC. Open the official past paper (linked at the top of this page) to read the question, then follow the worked solution below.
The underlying figure (intensity of the acute→chronic→granulation-tissue foreign-body response over time) is redrawn here from the paper's own seven-curve figure.
The figure shows the classic, conserved local cellular response to any implanted, non-degrading, non-integrating biomaterial, and silicone breast implants follow this sequence closely. Within minutes of implantation, plasma proteins adsorb onto the silicone surface (Vroman effect) and platelets and the coagulation cascade form a provisional fibrin matrix; a moderate initial level of circulating mononuclear leucocytes dips as they are recruited into the tissue and then remains low. Acute inflammation follows over the first hours: neutrophils infiltrate sharply and attempt to degrade what they cannot phagocytose, releasing reactive oxygen species and proteolytic enzymes at the implant surface, before dropping off. Over the following days, the response transitions to chronic inflammation, dominated by monocyte-derived macrophages; because the smooth, non-porous implant envelope presents a surface far larger than any single macrophage can engulf, macrophages undergo frustrated phagocytosis and fuse into multinucleated foreign body giant cells (FBGCs) that rise somewhat later and persist at the implant–tissue interface indefinitely (the implant is never actually degraded or cleared). Concurrently, neovascularization builds a capillary supply into the developing granulation tissue, and fibroblasts are recruited and, over subsequent weeks, deposit and remodel collagen into a dense, largely avascular fibrous capsule (rising last, as fibrosis) — the expected long-term end state for a smooth, non-porous, non-degrading, permanently implanted silicone device. These are, in themselves, normal foreign-body-response interactions, not evidence of disease; every non-integrating implant elicits this same capsule-forming sequence to some degree.
Two features of this otherwise-normal sequence provide biological plausibility for a link to autoimmune-type disease in a susceptible individual, while the direct epidemiological evidence for that link remains contested. First, silicone gel implants are known to undergo slow “gel bleed” and, particularly with capsular contracture or rupture, can shed microscopic silicone particles into the surrounding tissue and regional lymph nodes; these particles are taken up by macrophages and can sustain the chronic macrophage/FBGC activation shown in the figure indefinitely rather than allowing it to resolve, producing chronic local cytokine release (a granulomatous reaction, sometimes called siliconoma). Second, this persistent, low-grade immune activation has been proposed (the “Autoimmune/inflammatory Syndrome Induced by Adjuvants,” or ASIA, hypothesis) to act as a chronic adjuvant-like stimulus that, in a genetically or immunologically susceptible host, could in principle promote a break in self-tolerance (e.g. via bystander activation or exposure of previously sequestered self-antigens during chronic tissue remodelling), potentially contributing to a systemic autoimmune or connective-tissue-disease-like presentation. It is the chronic macrophage/FBGC-driven inflammatory phase of the response, sustained or amplified by any ongoing particle shedding, that is mechanistically the interaction most plausibly linked to a downstream autoimmune process — the acute neutrophil phase and the fibrous capsule formation itself are not, on their own, immune-antigen-specific events. That said, from a rigorous evidentiary standpoint, large epidemiological reviews (notably the U.S. Institute of Medicine's 1999 review) have not found a consistent, causal association between silicone breast implants and defined systemic connective-tissue/autoimmune diseases, so a materials-science assessment should present this mechanism as biologically plausible but epidemiologically unproven, rather than as an established causal pathway.
This illustrates the distinction between “biocompatible” and “biologically inert”: the fact that a material provokes no acute toxic or immediate hypersensitivity reaction does not mean it provokes no long-term biological consequence at all, and evaluating a chronic-implant material for a lifelong indication like breast augmentation requires assessing exactly this class of slow, cumulative interaction, not just short-term ISO 10993 cytotoxicity/irritation endpoints.
